NCT01989585 2026-03-19
Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
Clinical Trials
3 trialsNCT02079740 2025-09-30
Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1/2 Active not recruiting
NCT03366103 2023-10-17
Navitoclax and Vistusertib in Treating Patients With Relapsed Small Cell Lung Cancer and Other Solid Tumors
National Cancer Institute (NCI)
Phase 1/2 Terminated